Cargando…

CMR-Based Risk Stratification of Sudden Cardiac Death and Use of Implantable Cardioverter–Defibrillator in Non-Ischemic Cardiomyopathy

Non-ischemic cardiomyopathy (NICM) is one of the most important entities for arrhythmias and sudden cardiac death (SCD). Previous studies suggest a lower benefit of implantable cardioverter–defibrillator (ICD) therapy in patients with NICM as compared to ischemic cardiomyopathy (ICM). Nevertheless,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Keil, Laura, Chevalier, Céleste, Kirchhof, Paulus, Blankenberg, Stefan, Lund, Gunnar, Müllerleile, Kai, Magnussen, Christina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8268120/ https://www.ncbi.nlm.nih.gov/pubmed/34281168 http://dx.doi.org/10.3390/ijms22137115

Ejemplares similares

CMR feature tracking in patients with dilated cardiomyopathy: patterns of myocardial strain and focal fibrosis
por: Chevalier, Céleste, et al.
Publicado: (2022)

CMR feature tracking strain patterns and their association with circulating cardiac biomarkers in patients with hypertrophic cardiomyopathy
por: Cavus, Ersin, et al.
Publicado: (2021)

Predictors of Implantable Cardioverter-Defibrillator Use in Patients with Ischemic Cardiomyopathy
por: Kelly, Ryan, et al.
Publicado: (2010)

Implantable cardioverter-defibrillator prevents sudden death in patients with Chagas cardiomyopathy in the Brazilian Amazon
por: Couceiro, Katia do Nascimento, et al.
Publicado: (2021)

Implantable cardioverter–defibrillator in hypertrophic cardiomyopathy
por: Sanchez, Diego Jimenez, et al.
Publicado: (2018)

Impact of Cardiac Magnetic Resonance (CMR) on utilization of Implantable-Cardioverter-Defibrillators (ICD) for primary prophylaxis of sudden cardiac death
por: Ertel, Andrew, et al.
Publicado: (2013)

Incidence of appropriate cardioverter-defibrillator shocks and mortality in patients with implantable cardioverter-defibrillators with ischemic cardiomyopathy versus nonischemic cardiomyopathy at 33-month follow-up
por: Gandhi, Kaushang, et al.
Publicado: (2010)

Updated risk assessments for sudden cardiac death in hypertrophic cardiomyopathy patients with implantable cardioverter-defibrillator
por: Park, Yae Min
Publicado: (2023)

Impact of implantable cardioverter defibrillator on survival in patients with non‐ischemic dilated cardiomyopathy
por: Kataoka, Naoya, et al.
Publicado: (2023)

Higher defibrillation threshold in methamphetamine cardiomyopathy patients with implantable cardioverter-defibrillator
por: Malhotra, Rakesh, et al.
Publicado: (2017)

Clinical Risk Stratification for Primary Prevention Implantable Cardioverter Defibrillators
por: Lee, Douglas S., et al.
Publicado: (2015)

Selvester score predicts implantable cardioverter defibrillator shocks in patients with non‐ischemic cardiomyopathy
por: Arısoy, Fazıl, et al.
Publicado: (2021)

Role of Implantable Cardioverter Defibrillators in the Treatment of Hypertrophic Cardiomyopathy
por: Ghosh, Joydeep, et al.
Publicado: (2005)

Role of Cardiac Magnetic Resonance (CMR) in Determining Implantable Cardioverter-Defibrillator (ICD) Indication in Acromegalic Cardiomyopathy: A Case Report
por: Inoue, Naoto, et al.
Publicado: (2022)

Underutilization of Implantable Cardioverter Defibrillator in Primary Prevention of Sudden Cardiac Arrest
por: Lakshmanadoss, Umashankar, et al.
Publicado: (2011)

Myocardial Scar Characterization and Future Ventricular Arrhythmia in Patients With Ischemic Cardiomyopathy and an Implantable Cardioverter-Defibrillator
por: Noordman, Alwin B. P., et al.
Publicado: (2021)

Factors associated with implantable cardioverter-defibrillator shocks in patients suffering from non-ischemic cardiomyopathy
por: Rezaee, Mahmood, et al.
Publicado: (2022)

Primary prevention implantable cardioverter-defibrillator use in non-ischemic dilated cardiomyopathy based on arrhythmic risk stratification and left ventricular reverse remodeling prediction
por: Muhammed, Ahmed, et al.
Publicado: (2022)

Implantable cardioverter-defibrillators in non-ischaemic cardiomyopathy: a need or not?
por: de Groot, Joris R.
Publicado: (2023)

Survival Following Implantable Cardioverter‐Defibrillator Implantation in Patients With Amyloid Cardiomyopathy
por: Higgins, Angela Y., et al.
Publicado: (2020)

Implantable cardioverter-defibrillators /
Publicado: (1994)

Subcutaneous implantable cardioverter-defibrillator (S-ICD) for secondary prevention of sudden cardiac death
por: Kempa, Maciej, et al.
Publicado: (2016)

Implantable Cardioverter‐Defibrillators for Secondary Prevention of Sudden Cardiac Death: A Review
por: Borne, Ryan T., et al.
Publicado: (2017)

Use of Implantable Cardioverter-Defibrillators for Primary Prevention of Sudden Cardiac Death in Asia
por: Ueda, Nobuhiko, et al.
Publicado: (2023)

Clinical and Hospital Factors Affecting Treatment with Primary Prevention Implantable Cardioverter-Defibrillators in Ischemic Cardiomyopathy Patients
por: Lee, Jae-Hyuk, et al.
Publicado: (2020)

An implantable cardioverter-defibrillator for primary prevention in non-ischemic cardiomyopathy: A systematic review and meta-analysis
por: Wasiak, Michał, et al.
Publicado: (2023)

Implantable cardioverter defibrillator implantation and degree of left ventricular scarring predict survival in patients with severe ischemic cardiomyopathy
por: Kwon, Deboarh H, et al.
Publicado: (2011)

Sudden Cardiac Arrest in Hemodialysis Patients with Wearable Cardioverter Defibrillator
por: Wan, Chingping, et al.
Publicado: (2013)

Personalized Management of Sudden Death Risk in Primary Cardiomyopathies: From Clinical Evaluation and Multimodality Imaging to Ablation and Cardioverter-Defibrillator Implant
por: Lazzeroni, Davide, et al.
Publicado: (2023)

Subcutaneous Implantable Cardioverter Defibrillator in Patients With Hypertrophic Cardiomyopathy: An Initial Experience
por: Weinstock, Jonathan, et al.
Publicado: (2016)

Sudden Cardiac Death Risk over Time in HCM Patients with Implantable Cardioverter-Defibrillator
por: Klopotowski, Mariusz, et al.
Publicado: (2022)

Brugada Syndrome: The Role of Risk Stratification in Selecting Patients for Implantable Cardioverter-defibrillator Placement
por: Mankbadi, Michael, et al.
Publicado: (2018)

Deactivation of implantable cardioverter-defibrillators
por: Wan, Darryl, et al.
Publicado: (2021)

Performance of the PRIMaCY sudden death risk prediction model for childhood hypertrophic cardiomyopathy: implications for implantable cardioverter-defibrillator decision-making
por: Norrish, Gabrielle, et al.
Publicado: (2023)

The subcutaneous implantable cardioverter-defibrillator should be considered for all patients with an implantable cardioverter-defibrillator indication
por: Tan, Jian Liang, et al.
Publicado: (2022)

Implantable cardioverter defibrillator in nonischemic cardiomyopathy: A systematic review and meta‐analysis
por: Khan, Safi U., et al.
Publicado: (2017)

Response: Impact of implantable cardioverter defibrillator on survival in patients with nonischemic dilated cardiomyopathy
por: Salehi Omran, Hossein, et al.
Publicado: (2023)

Utilization and Outcomes of Primary Prevention Implantable Cardioverter‐Defibrillators in Patients With Hypertrophic Cardiomyopathy
por: Goldstein, Sarah A., et al.
Publicado: (2023)

Implantation of Implantable Cardioverter Defibrillators in Kazakhstan
por: Begisbayev, Temirkhan, et al.
Publicado: (2022)

Implantable cardioverter defibrillator for primary prevention in patients with non-ischemic cardiomyopathy in the era of novel therapeutic agents- meta-analysis
por: Kolben, Yotam, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_0mbt7k6lqpnd2aof9q671g7rfp